12/12
07:00 pm
hcm
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
Low
Report
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
12/11
11:00 pm
hcm
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
Low
Report
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
12/3
07:04 pm
hcm
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
Medium
Report
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
12/3
07:00 pm
hcm
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Low
Report
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
12/3
07:00 pm
hcm
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Low
Report
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
12/3
05:05 am
hcm
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
Low
Report
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer [Yahoo! Finance]
12/3
05:00 am
hcm
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
Low
Report
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
11/28
05:34 am
hcm
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms [Yahoo! Finance]
Medium
Report
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms [Yahoo! Finance]
11/28
05:30 am
hcm
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
Medium
Report
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
11/21
11:30 pm
hcm
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
Low
Report
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
11/20
04:30 am
hcm
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Low
Report
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
11/19
12:09 am
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/5
11:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
11/4
11:14 pm
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/31
04:38 am
hcm
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
Medium
Report
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
10/31
04:30 am
hcm
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
Medium
Report
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
10/16
12:30 am
hcm
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
Medium
Report
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
9/24
03:00 am
hcm
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Medium
Report
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda